Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rovalpituzumab tesirine

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

Pharma deals in April 2015

The love affair with oncology continues, finds Medius Deal Watch

Medius Deal Watch table for April 2015

The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology

Pharma deals in March 2015

AbbVie's Pharmacyclics mega-merger dominated the month, finds Medius Deal Watch

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

Pharma deals in February 2015

Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations

Medius Deal Watch table for February 2015

The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

- PMLiVE

Survey reveals problems with lung cancer mutation testing

A quarter of patients surveyed not receiving EGFR testing prior to treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links